

Add to Cart
Premarket tobacco application (PMTA1) refers to the application
under Section 910(a)(2) of the Federal Food, Drug, and Cosmetic Act
(FD&C Act) on February 15, 2007. If a new tobacco product (New
Tobacco Product) is to be sold legally in the United States, it
must submit an application to the US Food and Drug Administration
(US FDA2), review and obtain approval.
Note:
1. PMTA is one of the three ways to apply for marketing of new
tobacco products. The other two are SE (Substantial Equivalence,
proving substantial equivalence) and EX REQ (RequestExemption from
Demonstrating Substantial Equivalence, requesting exemption to
prove substantial equivalence). So far, all ENDS (Electronic
Nicotine Delivery System, also called Vapes) approved for marketing
have gone through the PMTA route.
2. According to the US federal "Family Smoking Prevention and
Tobacco Control Act" (the Family Smoking Prevention and Tobacco
Control Act), it grants the US Food and Drug Administration FDA the
power to regulate tobacco products, allowing the FDA to agree or
reject risk-modified tobacco products application and passed the
final deeming rule (81FR 28973) to extend its tobacco product
management authority to all products except accessories of deemed
tobacco products (also including e-cigarette ENDS) . The rule also
grants FDA discretion over the sale and distribution of
unsubstantiated modified risk tobacco products (MRTPs).
To make a determination and authorize marketing, FDA considers,
among other things, the following 4 points (under section
910(c)(4)):
1) the risks and benefits to the entire population, including
people who use the proposed new tobacco product as well as
non-users;
2) whether people who currently use any tobacco product would be
more or less likely to stop using the product they are currently
using if the proposed new tobacco product comes to market;
3) whether people who do not currently use any tobacco products
will start using tobacco products to a greater or lesser extent if
a new tobacco product becomes available;
4) Methods, equipment and controls used to manufacture, process and
package new tobacco products.
the Final PMTA Rules
In 2021, FDA determines the final PMTA rules, namely: Premarket
Tobacco Product Applications and Recordkeeping Requirements.
1) This rule specifies the content (Content), format (Format) and
review (Review) format required for PMTA.
2) In order for FDA to complete a substantive review of the PMTA,
the application must include the information mentioned in the final
rule.
3) The rule also requires manufacturers to maintain records to
prove that their tobacco products are legally sold.
4) The final PMTA rule also includes information on how to amend or
withdraw an application, how FDA communicates with applicants, and
FDA’s disclosure procedures.
Preparing and Submitting a PMTA
In October 2023, the FDA's Center for Tobacco Products (CTP)
released the sixth edition of the "Electronic Submission File
Formats And Specifications" document, which clarified the relevant
requirements for electronic submissions. Detailed explanations,
especially demonstrations of Heading of Contents and Hierarchic.
✓ For example, the electronic document should contain 7 templates:
1) Module 1: Administrative information (Module 1: Administrative)
2) Module 2: Summary (Module 2: Summary)
3) Module 3: Product Description and Manufacturing
4) Module 4: Nonclinical
5) Module 5: Clinical - Product Impact on Individual Health (Module
5: Clinical - Product Impact on Individual Health)
6) Module 6: Clinical – Product Impact on Population Health) 7)
Module 7: Environmental Impact (Module 7: Environmental Impact)
✓ Electronic submission tool: eSubmitter Software
✓ Data submission platform: CTP Portal
FDA has also prepared a large amount of information and resources
to support applicants in preparing and submitting PMTAs, such as:
1) Standard PMTA preparation process
2) Supplement and resubmit PMTA process
3) Revision preparation process
4) Process for submitting PMTAs and revisions
5) Additional resources to help prepare and submit a PMTA
PMTA Review Procedure
The PMTA review process can be roughly divided into 5 stages and 6
processes, as follows:
Stage 0: Pre-submission Meetings (Process 1)
A formal Voluntary meeting conducted by the applicant and FDA
(specifically Staff from CTP’s Office of Science) to discuss the
PMTA of the tobacco product planned to be submitted.
The FDA has strict requirements on meeting content. Before the
meeting, all types of materials should be prepared in accordance
with FDA requirements (official guidance documents are available:
Guidance for Industry and Investigators). Meeting formats include
conference calls, meetings at FDA offices, video conferences, or
written responses. Meeting length is typically 1 hour.
Process output file:
Meeting granted letter
Meeting denial letter
Meeting minutes letter (if meeting is granted and held) (Meeting
minutes letter (if meeting is granted and held))
Stage 1: Acceptance Review (Process 2)
Pass a preliminary review to ensure that the product falls within
the jurisdiction of the CTP and comply with Section 910 of the
FD&C Act: Application for Review of Certain Tobacco Products
and 21 CFR §1114.27 Review Procedure Part (a): Acceptance review in
the Review procedure) to confirm whether the requirements of the
Act and the procedure have been met.
Process output file:
Acceptance letter
Refuse to accept (RTA) letter
Stage 2: Filing Review (Filing Review) (Process Three)
This stage is to confirm whether the application contains
sufficient information and has reached the threshold of substantive
review (samples are required at this stage). FDA may deny
filing/filing if any of the conditions described in 21 CFR §1114.27
Part (b) of the Review Procedure: Filing Review in the Review
procedure arise.
Process output file:
Filing letter (Filing letter)
Stage 3 of Refuse to file (RTF) letter: Application Review and
Action
A. Application Review (Process 4)
FDA will evaluate the information and data in the application
document and will also consult the Tobacco Product Scientific
Advisory Committee
Advisory Committee (TPSAC)).
Process output file:
Deficiency letter/Deficiency letter: FDA will issue supplementary
requirements for the information submitted by the applicant to
complete the scientific review. and this
The letter will specify the deadline within which the applicant
must respond.
Environmental information request letter (Environmental
information request letter): If the submitted information is
scientific and complete, the FDA will issue a marketing
authorization order (marketing granted order) after scientific
evaluation—but before this, the applicant needs to submit a report
on environmental impact Report.
B. Action/Judgment (Action) (Process 5)
The FDA will rule on all information and processes as to where the
product ends up.
Process output file:
Marketing granted order letter (MGO)
Marketing denial order letter (MDO)
Stage 4: Postmarket Requirements (Process 6)
FDA requires applicants to establish and maintain product data and
submit reports upon FDA's request to determine or assist in
determining whether FDA has grounds to withdraw or temporarily
suspend a marketing authorization order. 21 CFR §1114.41 Reporting
requirements (Reporting requirements) specify the specific
requirements for reports to be submitted, such as: clear
organization, clear handwriting, and writing in English, etc.
If the document is translated from another language, the source
document must be submitted together with the translation, and a
statement must be provided that the information in the English
version is complete and accurate.
Also submitted together with the translator's qualification
certificate.
There are two types of reports submitted:
Periodic reports
Serious and unexpected adverse experience reporting (Serious and
unexpected adverse experience reporting)
Replenish:
Submission Tracking Number (STN) refers to the code assigned by the
system after FDA receives the applicant's information, such as PMTA
or supplementary PMTA, and undergoes preliminary review by the
system. Primarily used to identify any previously submitted
information about tobacco products that matches the applicant. This
process occurs around Phase 0 (i.e. before or after the meeting).
Getting an STN is just the beginning of a PMTA.
Harmful or Potentially Harmful Constituents (HPHCs) refers to any
compound in tobacco products or tobacco smoke or emissions that:
(1) is or may be inhaled, ingested or absorbed into the body,
including as aerosols or any other releases, and (2) cause or are
likely to cause direct or indirect harm to users or non-users of
tobacco products.
In compliance with the requirements of the FD&C Act, the FDA
has developed a list of HPHCs for tobacco products and tobacco
smoke, which currently totals 93 items. For ENDS, in order to help
the FDA assess potential health risks and facilitate the FDA's
assessment of whether new tobacco products are suitable for
protecting public health (APPH) (Appropriate for the Protection of
the Public Health, APPH), the FDA recommends that applicants submit
at least 38 copies of e-cigarette liquids and aerosols. Test data
(36 substances plus the pH value of the smoke liquid and Total
Particulate Matter (TPM) - that is, the content of particulate
matter in the smoke. The same as the environmental monitoring
quality indicator PM2.5 or PM10 content, TPM It is one of the main
quality indicators for measuring smoke in electronic cigarette
products).